{"category":[{"coding":[{"display":"REG536"}],"text":"Regulation Code"}],"condition":[{"coding":[{"display":"Locally-Advanced or Metastatic breast cancer (MBC)"}],"text":"Disease Condition"},{"coding":[{"code":"10070575","display":"MedDRA","system":"http://terminology.hl7.org/CodeSystem/mdr","version":"2.0.1"},{"code":"10065430","display":"MedDRA","system":"http://terminology.hl7.org/CodeSystem/mdr","version":"2.0.1"}],"text":"MedDRA Condition"}],"contact":[{"name":"Head of EU Trial Information Support Line-TISL, Switzerland","telecom":[{"system":"phone","use":"work","value":"0041616881111"},{"system":"email","use":"work","value":"global.rochegenentechtrials@roche.com"}]},{"extension":[{"url":"https://ansforge.github.io/IG-essais-cliniques/ig/main/StructureDefinition-eclaire-contact-type.html","valueCodeableConcept":{"coding":[{"code":"SCI","display":"Scientifique / Scientific","system":"https://ansforge.github.io/IG-essais-cliniques/ig/main/CodeSystem-eclaire-type-contact-code-system.html","version":"0.1.0"}],"text":"Contact Type"}}],"name":"INDISPONIBLE INDISPONIBLE","telecom":[{"system":"phone","use":"work","value":"INDISPONIBLE"},{"system":"email","use":"work","value":"INDISPONIBLE"}]}],"contained":[{"actual":true,"characteristic":[{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"code":"male","display":"Male","system":"http://hl7.org/fhir/administrative-gender","version":"5.0.0"},{"code":"female","display":"Female","system":"http://hl7.org/fhir/administrative-gender","version":"5.0.0"}],"text":"Genders"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueRange":{"high":{},"low":{"comparator":">=","unit":"years","value":65}}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueRange":{"high":{"comparator":"<=","unit":"years","value":64},"low":{"comparator":">=","unit":"years","value":18}}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"display":"Donn√©es non disponible"}],"text":"Research Study Group Category"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"display":"Women of child bearing potential not using contraception, Women of child bearing potential using contraception"}],"text":"Study Population"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false,"valueCodeableConcept":{"coding":[{"display":"INDISPONIBLE"}],"text":"Study Inclusion Criteria"}},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":true,"valueCodeableConcept":{"coding":[{"display":"INDISPONIBLE"}],"text":"Study Exclusion Criteria"}}],"id":"2022-500014-26-00-enrollment-group-id","quantity":21,"type":"person","resourceType":"Group"}],"description":"INDISPONIBLE","enrollment":[{"display":"Reference to group detailing study characteristics","reference":"#2022-500014-26-00-enrollment-group-id","type":"Group"}],"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-secondary-sponsor","valueReference":{"display":"Reference to secondary sponsor","reference":"Organization/2022-500014-26-00-secondary-sponsor","type":"Organization"}},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area","valueString":"Diseases [C] - Neoplasms [C04]"}],"id":"2022-500014-26-00","identifier":[{"assigner":{"display":"INDISPONIBLE"},"use":"official","value":"INDISPONIBLE"},{"assigner":{"display":"euclinicaltrials.eu","reference":"https://euclinicaltrials.eu/app/#/view/2022-500014-26-00"},"use":"secondary","value":"2022-500014-26-00"}],"meta":{"lastUpdated":"2023-04-12T00:00:00.000Z","profile":["https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"]},"phase":{"coding":[{"code":"phase-3","display":"Phase 3","system":"http://terminology.hl7.org/CodeSystem/research-study-phase","version":"4.0.1"}],"text":"Therapeutic confirmatory  (Phase III)"},"referenceContents":{"organizations":[{"active":true,"address":[{"city":"Basel Town","country":"Switzerland","postalCode":"4058","text":"Grenzacherstrasse 124 Basel Town 4058 Switzerland","type":"physical","use":"work"}],"contact":[{"name":{"family":"Trial Information Support Line-TISL, Switzerland","given":["Head of EU"],"text":"Head of EU Trial Information Support Line-TISL, Switzerland","use":"official"},"purpose":{"coding":[{"code":"ADMIN","display":"Administrative","system":"http://terminology.hl7.org/CodeSystem/contactentity-type","version":"4.0.1"}],"text":"Organization Contact Purpose"},"telecom":[{"system":"phone","use":"work","value":"0041616881111"},{"system":"email","use":"work","value":"global.rochegenentechtrials@roche.com"}]}],"id":"2022-500014-26-00-primary-sponsor","name":"F. Hoffmann-La Roche AG","type":[{"coding":[{"code":"crs","display":"Clinical Research Sponsor","system":"http://terminology.hl7.org/CodeSystem/organization-type","version":"4.0.1"}],"text":"Organization Sponsor Type"}],"resourceType":"Organization"},{"active":true,"address":[{"city":"INDISPONIBLE","country":"INDISPONIBLE","postalCode":"INDISPONIBLE","text":"INDISPONIBLE INDISPONIBLE INDISPONIBLE INDISPONIBLE","type":"physical","use":"work"}],"contact":[{"name":{"family":"INDISPONIBLE","given":["INDISPONIBLE"],"text":"INDISPONIBLE INDISPONIBLE","use":"official"},"purpose":{"coding":[{"code":"ADMIN","display":"Administrative","system":"http://terminology.hl7.org/CodeSystem/contactentity-type","version":"4.0.1"}],"text":"Organization Contact Purpose"},"telecom":[{"system":"phone","use":"work","value":"INDISPONIBLE"},{"system":"email","use":"work","value":"INDISPONIBLE"}]}],"id":"2022-500014-26-00-secondary-sponsor","name":"INDISPONIBLE","type":[{"coding":[{"code":"crs","display":"Clinical Research Sponsor","system":"http://terminology.hl7.org/CodeSystem/organization-type","version":"4.0.1"}],"text":"Organization Sponsor Type"}],"resourceType":"Organization"}]},"sponsor":{"display":"Reference to primary sponsor","reference":"Organization/2022-500014-26-00-primary-sponsor","type":"Organization"},"title":"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER","resourceType":"ResearchStudy","status":"active"}
